2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Ephrin Receptor
  5. Ephrin Receptor Isoform

Ephrin Receptor

 

Ephrin Receptor Related Products (31):

Cat. No. Product Name Effect Purity
  • HY-18007
    ALW-II-41-27
    		Inhibitor 99.33%
    ALW-II-41-27 is a Eph family tyrosine kinase inhibitor with an IC50 of 11 nM for Eph2.
  • HY-13258A
    NVP-BHG712
    		Inhibitor 99.71%
    NVP-BHG712 is an oral active EphB4 kinase autophosphorylation inhibitor, with IC50 values of 3.3 nM and 3.0 nM for EphA2 and EphB4, respectively.
  • HY-18833
    ALW-II-49-7
    		Inhibitor 99.97%
    ALW-II-49-7 is a selective EphB2 kinase inhibitor with an EC50 value of 40 nM in cell.
  • HY-18832
    AWL-II-38.3
    		Inhibitor 99.71%
    AWL-II-38.3 is a potent ephrin-A receptor (EphA3) kinase inhibitor. AWL-II-38.3 does not exhibit significant cellular activity against Src-family kinases nor against b-raf.
  • HY-107460
    LDN-211904 oxalate
    		Inhibitor 99.0%
    LDN-211904 oxalate is a potent and reversible EphB3 inhibitor with an IC50 of 79 nM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with Cetuximab (HY-P9905) could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab resistance in CRC.
  • HY-P991577
    DS-8895
    		Inhibitor
    DS-8895 is an anti-EphA2 monoclonal antibody. DS-8895 allows noninvasive measurement of EphA2 expresssion in tumors in vivo. DS-8895 can be studied in research for advanced solid cancers positive to EphA2.
  • HY-P10412A
    A11 acetate
    		Inhibitor 98.48%
    A11 (ANXA1-derived 11 amino acid-long peptide) acetate is an ANXA1-EphA2 interaction blocker peptide. A11 acetate decreases ANXA1 bound to EphA2 and increased Cbl (an E3 ubiquitin ligase of EphA2) bound to EphA2. A11 efficiently decreases EphA2 level, and substantially increases EphA2 ubiquitination. A11 acetate increases EphA2 internalization and colocalization of EphA2 and Cbl in the NPC cells. A11 acetate inhibits nasopharyngeal carcinoma (NPC) cell proliferation, migration and invasion. A11 acetate inhibits angiogenesis.
  • HY-P10960
    Nuzefatide
    		Ligand
    Nuzefatide is an ephrin receptor binding peptide.
  • HY-P0177
    123C4
    		Agonist 99.46%
    123C4 is a potent, selective and competitive agonist of the receptor tyrosine kinase EPHA4, with a Ki value of 0.65 μM.
  • HY-13258
    NVP-BHG712 isomer
    		99.58%
    NVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4.
  • HY-P990627
    Anti-EphA2 Antibody (1C1)
    Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is a humanized antibody expressed in CHO cells, targeting EphA2. Anti-EphA2 Antibody (1C1) contains huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 146.68 kDa. The isotype control for Anti-EphA2 Antibody (1C1) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-147637
    EphA2 agonist 1
    		Agonist 99.32%
    EphA2 agonist 1 (Compound 7bg) is a potent EphA2 receptor agonist. EphA2 agonist 1 shows great potency and selectivity toward EphA2 overexpressed glioblastoma cells and stimulates EphA2 phosphorylation.
  • HY-123607
    UniPR129
    		Antagonist 99.23%
    UniPR129 is a potent and orally active Eph/ephrin antagonist. UniPR129 can inhibit EphA2-ephrin-A1 interaction with an IC50 of 945 nM and a Ki of 370 nM. UniPR129 can inhibit angiogenesis and show antitumor and neuroprotective effect. UniPR129 can be used for the researches of cancer and neurological disease, such as colorectal cancer and optic neuropathy.
  • HY-114199
    Eph inhibitor 1
    		Inhibitor 99.92%
    Eph inhibitor 1 is a potent Eph inhibitor. Eph inhibitor 1 has the potential for the research of neurological disorders.
  • HY-P3717
    Targefrin
    		99.80%
    Targefrin is a potent EphA2-targeting agent, acts as an antagonist. Targefrin binds EphA2-LBD with 21 nM dissociation constant and an IC50 value of 10.8 nM. Targefrin induces cellular receptor internalization and degradation in several pancreatic cancer cell lines.
  • HY-P2264
    KYL peptide
    		Inhibitor 99.65%
    KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor (IC50:4.22 μM, Kd:1.3 μM). KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. KYL peptide can promote nerve regeneration after injury and modulating immune responses.
  • HY-169849
    EphA2 antagonist 1
    		Inhibitor
    EphA2 antagonist 1 (4b) is a bile acid conjugate and an ephrin type-A receptor 2 (EPHA2) inhibitor.
  • HY-131005
    Eph inhibitor 2
    		Inhibitor 99.00%
    Eph inhibitor 2 (Example 35) is a Eph family tyrosine kinase inhibitor.
  • HY-157019
    UniPR1447
    		Antagonist 99.46%
    UniPR1447 is Dual EphA2 and EphB2 antagonist, with an IC50 of 6.6 μM for EphA2−ephrin-A1 binding.
  • HY-P10579
    123B9
    		Agonist 99.67%
    123B9, a tumor-homing agent, is a potent and selective EphA2 agonist with a Kd value of 4.0 μM. 123B9 selectively targets the EphA2 tyrosine kinase receptor ligand-binding domain. 123B9 does not appreciably inhibit the ligand binding domains of the most closely related EphA3 and EphA4 receptors.